Vietnam Drug Makers Hurt By Ban On Retail Price Increases
This article was originally published in PharmAsia News
Executive Summary
Vietnam's drug-making industry is feeling the pain of the government's ban on price increases at the retail level. Drug manufacturers as well as importers, said an industry member at a Drug Administration of Vietnam conference, are being hit by high inflation and an ever-changing exchange rate at the same time. Many drug makers, he said, are forced to use the black market to get the foreign currency they need to buy drugs from abroad. Another noted the price of raw materials needed by local drug makers cost as much as six times more than a year ago. (Click here for more
You may also be interested in...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.